Search Results

You are looking at 21 - 30 of 134 items for :

  • "shared decision-making" x
  • Refine by Access: All x
Clear All
Full access

Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Albert C. Koong, and Mary Frances McAleer

work evaluates specific clinical factors associated with early and midtreatment mortality, with the goal of helping guide formal communication in EoL care and shared decision-making strategies for terminally ill patients with cancer. Materials and

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar, and Susan Darlow

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.

Full access

Rodger J. Winn

States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE), a national disease registry . J Urol 2004 ; 171 : 1393 – 1401 . 5 Barry MJ . Health decision aids to facilitate shared decision making in office

Full access

Jonas A. de Souza, Colleen Kelly, and Chadi Nabhan

.10 months. If the shared decision-making process were solely based on survival, FOLFIRINOX would be selected in every case. However, this decision should incorporate other elements, including costs and adverse events. Relative cost is computed in a similar

Full access

Robin M. Lally, Elizabeth Reed, and Roksana Zak

-based care, multidisciplinary approach, variability for patient preferences, promotion of patient-provider communication and shared decision-making. Stakeholders were also involved by engaging “champion” physicians at the rural centers to encourage pathway

Full access

Guidelines into Evinance's Decision Support system will directly benefit both clinicians and patients by offering evidence-based clinical recommendations at the point of care, as well as empowering patients to partake in the shared decision-making process to

Full access

options and take part in informed, shared decision-making,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Spreading the word about our resources at the point of care, when patients and providers are most primed to act, will enable us to

Full access

Fumiko Chino

launched as a physician-guided tool to facilitate open dialogue between physicians and patients in selecting high-value cancer treatment. 1 Shared decision-making is crucial in the modern era of cancer therapy, where proliferating options for disease

Full access

recognized by key stakeholders in oncology, a variety of whom have begun to develop value tools and calculators to determine the most valuable treatment options. Intended for use in the shared decision-making process, these tools must reflect the most